Early studies looking at CSF p‐tau concentrations in AD using ELISA revealed that irrespective of which p‐tau epitope was measured, p‐tau is significantly elevated in AD compared with age‐matched CU controls, as well as patients with non‐AD dementias [109, 110, 116, 117, 118]. This evidence concerns the gene MAPT and Alzheimer disease.